Preferences help
enabled [disable] Abstract
Number of results
2016 | 53 | 3 | 384-403
Article title

Epidemiological analysis of the environmental health impact of annual ivermectin mass drug administration on clinical manifestation of onchocerciasis

Title variants
Languages of publication
Epidemiological studies on the impact of onchocerciasis control in some parts of Imo State, Nigeria was undertaken between 2008 and 2012 to determine the impact of annual ivermectin mass drug administration on clinical manifestation of Onchocerciasis. The survey took place in the nine villages of Okigwe local government area, which have base line data at Carter Center Imo/Abia project. Permission to carry out this survey was obtained from Ministry of Health as well as informed consent was obtained from the individual volunteers. Skin snip for microfilaria (mf), community microfilaria load (cmfl), physical examination, visual screening, were carried out among 960 volunteers comprising of 511 males and 499 females from age group 5-62+ in the sampled villages in accordance with the epidemiological evaluation of onchocerciasis protocol. The results shows 63.7% reduction against 47.2% nodule prevalence in 1995 to 14.3% nodule prevalence in 2012 (p<0.001). Similarly there is 36.3% reduction rate of mf prevalence from 51.8% mf rate to 33.0% in 2012 after 15 years of mass drug administration (p<0.005). CMFL is generally low among the sampled villages 0.90 mf per milligram (p<0.001). An Onchocercal symptom was found among individuals in the sampled villages 47.2%. Also mf prevalence was rare in age group 5-15(17%), subsequently increased with age and highest in age group 56-62+ (26%). However, because microfilaria (mf) was found among the subjects, is suggestive of its potential continued transmission and therefore Onchocerciasis is not yet eliminated.
Physical description
  • Department of Animal and Environmental Biology, Imo State University, Owerri, Nigeria
  • Department of Biological and Environmental Sciences, Kampala International University, Kampala, Uganda,
  • The Carter Centre South-East Integrated Programs, Owerri, Nigeria
  • Department of Biological Sciences, Anambra State University, Uli, Nigeria
  • [1] Chavasse D.C., Post R.J. Lemoh P.A., Whitworth J.A.G, (1992). The effect of repeated doses of ivermectin on adult female Onchocerca volvulu in Sierra Leone. Trop. Med. Parasit. 43: 256-262.
  • [2] Crosskey R.W., Crosskey M.E., (1959). A quantitative survey of Onchocerciasis in persons under twenty years of age in an endemic area in Northern Nigeria. Ann. Trop. Med. Parasit. 53: 10-24.
  • [3] Cupp E.W. Bernardo M.J., et al. (1995). The effects of ivermectin on Transmission of Onchocerca volvulus science No 3: 13-5.
  • [4] Duke B.O., Zea-Flores G., Castro J., Cupp E.W., Munoz B., (1992). Effects of three month doses of ivermectin on adult Onchocerciasis volvulus. Ann. J. Trop. Med. Hyg. 46(2): 189-194.
  • [5] Duke B.O.L, Zea-Flores G., Castro J., Cupp E.W., Munoz B., (1990). Effects of Multiple monthly doses of ivermectin on adult Onchocerca volvulus. Ann. J. Trop. Med. Hyg. 43(6): 90-142.
  • [6] Emukah. E. et al; (2004). A longitudinal study of impact of repeated mass Ivermectin treatment on clinical manifestations of Onchocerciasis in Imo State, Nigeria: Annl. J. Trop. Med. Hyg. 70(5): 556-561.
  • [7] Epidemiology of human Onchocerciasis on the Jos Plateau Nigeria II season relatives’ abundance and ineffective biting pattern of Simulium damnosum complex Nigerian Journal of parasitology, 7(1) (1986).
  • [8] Fuglsang, H. (1983). “Leopard skin” and Onchocerciasis. Trans. of Roy. Soc. Trop. Med. Hyg. 77: 881.
  • [9] Goa K.L. Mc Tavish D. Clissold S.P. (1991). Ivermectin-A review of its antifilarial activity, pharmacokinetic properties and clinical efficacy in onchocerciasis. Drugs. granding system of the cutaneous changes in onchocerciasis. British Journal of Dermatology 129: 250-269.
  • [10] Habbaema J.D.F. (1995). Irreversible effects of ivermectin on adult parasites in Onchocerciasis patients in the Onchocerciasis control programme in West Africa. J. Inf. Dis 172: 204-210.
  • [11] J. D. Smith; Animal Parasitology 3rd edition (1976) pg. 423-436. Merck Sharp Dohme and Co. Inc. USA: Hope for patients suffering from Onchocerciasis a vision for Tomorrow MSD 1991.
  • [12] Merck Sharp Dohme and Co. INC. USA: STROMECTOL, (Ivermectin) MSD 1996.
  • [13] Murdoch M.E., Hay R.J. Mackenze C.D.A, (1993): Clinical Classification and
  • [14] Nwoke B.E.B (1992). Musculo-skeletal pain (MSP) in Onchocerciasis. A potential in the rapid low cost epidemiological survey and in the assessment impact of mectizan treatment in a community, angewante parasital. (Germany) 33: 133-138.
  • [15] Nwoke B.E.B, (1994). Rapid Epidemiology Mapping of Onchocerciasis (REMO) in South-eastern Zone of NOCP Nigeria. Technical Report National Onchocerciasis control Programme (NOCP) Federal Ministry of Health, Lagos Nigeria, P.122.
  • [16] Nwoke, B.E.B. and Dozie, I.N.S (2001). Operational Research and its success in Onchocerciasis control in Nigeria. The Nig Journal of parasitology, 22 (1&2): 3-10.
  • [17] Nwoke, BEB Onwuliri, COE and Iwuala, MOE (1986a). Studies on the field
  • [18] Plaisier A.P., Alley, E.S, Boatin B.A., Van Oartmarssen, Remme H., De Vlas S.J., Bonneux, L., (1995). Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the onchocerciasis control programme in West Africa. J. Inf. Dis. 172: 204-10.
  • [19] Schulz-key H. (1988). The collagenase technique; how to isolate and examine adult onchocerca volvulus for the evaluation of drug effects. Trop Med. Parasit. 39: 423-440.
  • [20] Taylor H.R. Semba, R.D, Newland H.S. (1987). Ivermectin Treatment of patient with severe ocular Onchocerciasis. AM. J. Trop. Med. Hyg. 1987: 494-500.
  • [21] Taylor H.R., Pacque M., Munoz B. Green B.M., (1990). Impact of mass treatment of Onchocerciasis with ivermectin on the transmission of infection. Sci. 250: 116-118.
  • [22] Ukaga C.N. Onchocerciasis Musculo Skeletal pains in women. Africa Health March 1997, Vol. 19 No. 3: 16. WHO publication. 126 p.
  • [23] World Health Organization (1976). Epidemiology of onchocerciasis. Report of WHO expert committee. Technical Report series: 542.
  • [24] World Health Organization (1989). Report of a meeting of the TDR/OCP/OCTsubcommittee for monitoring of community trials of ivermectin. Geneva: WHO, Publication no. TDR/OCP/ OCT/ IVERMECTIN/89.3.
  • [25] World Health Organization (1990). Drugs used in parasitic diseases. Geneva.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.